Hypothesis

mTORC1 activity does not merely toggle between a static ‘civilization’ (growth) and ‘survival’ (catabolism) mode; instead, it drives a circadian oscillation that periodically remodels the epigenetic landscape at the CDKN2A/B locus through a SIRT1‑dependent regulation of EZH2 histone methyltransferase activity. During the fed phase, mTORC1 activation transiently suppresses SIRT1, reducing EZH2 deacetylation and thus lowering H3K27me3 deposition, which permits a pulse of CDKN2A/B transcription that facilitates the removal of damaged cells via senescence‑associated secretory phenotype (SASP)‑mediated immune clearance. In the fasted phase, mTORC1 inhibition allows SIRT1 to reactivate, deacetylate EZH2, boost its methyltransferase activity, and re‑establish H3K27me3‑mediated silencing, thereby resetting the locus for the next growth cycle. Disruption of this rhythmic epigenetic gating—by chronic mTORC1 inhibition, constant activation, or loss of SIRT1—locks CDKN2A/B in either a permanently silenced state (impairing senescence‑dependent tumor surveillance) or a constitutively active state (driving premature tissue aging).

Mechanistic Rationale

1. mTORC1‑SIRT1 Crosstalk – mTORC1 phosphorylates and inhibits the upstream AMPK activator LKB1, decreasing NAD+ levels and SIRT1 activity (1). Conversely, fasting raises NAD+, activating SIRT1.
2. SIRT1 Regulates EZH2 – SIRT1 deacetylates EZH2 at lysine residues critical for its catalytic function, enhancing H3K27me3 transferase activity (2). Acetylated EZH2 is less efficient at methylating H3K27.
3. Circadian Feeding/Fasting Drives Oscillations – In mice, hepatic mTORC1 activity peaks during the dark (fed) phase and troughs during the light (fasted) phase, mirroring SIRT1 oscillations (3).
4. CDKN2A/B Chromatin State – The CDKN2A promoter harbors a CpG island flanked by PRC2‑targeted nucleosomes; H3K27me3 levels here are dynamic and correlate inversely with p16INK4a mRNA in young tissues but become uncoupled in aged or SIRT1‑deficient models (4).
5. Feedback via pRB – Transient p16INK4a pulses during fed phases activate CDK4/6 inhibition, promoting a reversible cell‑cycle arrest that facilitates SASP release and immune clearance without committing to permanent senescence; sustained EZH2 activity during fasting restores repression, preventing arrest consolidation.

Testable Predictions

• Prediction 1: In wild‑type mice, ChIP‑seq for H3K27me3 at the CDKN2A/B promoter will show a significant trough (≈30% reduction) at ZT6–ZT10 (peak feeding) and a peak (≈20% increase) at ZT18–ZT22 (peak fasting), inversely mirroring p16INK4a mRNA levels measured by qRT‑PCR.
• Prediction 2: Liver‑specific SIRT1 knockout will abolish the H3K27me3 oscillation, resulting in constitutively low H3K27me3 and elevated baseline p16INK4a, accompanied by increased SA‑β‑gal positivity and reduced proliferative capacity after partial hepatectomy.
• Prediction 3: Pharmacological mTORC1 inhibition (rapamycin) administered continuously will lock H3K27me3 at high levels, suppress p16INK4a pulses, and impair clearance of senescent cells after irradiation, leading to accumulation of SASP‑positive cells despite lower p16INK4a transcription.
• Prediction 4: Timed rapamycin delivery restricted to the fed phase will preserve the H3K27me3 oscillation and enhance senescent cell clearance compared with constant dosing, as measured by flow cytometry for p16INK4a‑positive immune‑cleared cells.

Experimental Approach

1. Animal Models – Use Cre‑loxP lines for liver‑specific SIRT1 knockout (SIRT1^fl/fl; Alb‑Cre) and inducible mTORC1^CA (Rheb^CA) mice.
2. Circadian Sampling – Collect tissues every 4 h over 24 h under 12 h light/dark cycles; perform ChIP‑seq for H3K27me3 and acetyl‑EZH2, RNA‑seq for CDKN2A/B, and SASP cytokine profiling.
3. Functional Assays – Measure hepatocyte proliferation (BrdU incorporation) after partial hepatectomy, senescent cell burden (SA‑β‑gal, p16INK4a‑GFP reporter), and immune cell infiltration (flow cytometry for CD8⁺, NK cells).
4. Interventions – Administer rapamycin either continuously or in timed pulses (ZT4–ZT8) and assess outcomes above.

Implications

If validated, this hypothesis reframes mTORC1 not as a simple longevity switch but as a metronome that synchronizes growth‑associated epigenetic remodeling with autophagic clearance, ensuring that senescence is employed transiently as a tissue‑renewal tool rather than a chronic detriment. It suggests that chronotherapeutic mTOR modulation—aligning drug timing with natural feeding/fasting cycles—could preserve the beneficial, oscillatory senescent response while mitigating the deleterious effects of constant mTOR inhibition or activation. Conversely, loss of SIRT1 or disrupted circadian feeding (e.g., shift work, high‑frequency snacking) would predict accelerated aging through a locked CDKN2A/B state, providing a mechanistic link between circadian metabolic disorders and age‑related pathology.